Autoantibodies against chemokines post-SARS-CoV-2 infection correlate with disease course
-
Published:2023-03-06
Issue:4
Volume:24
Page:604-611
-
ISSN:1529-2908
-
Container-title:Nature Immunology
-
language:en
-
Short-container-title:Nat Immunol
Author:
Muri JonathanORCID, Cecchinato ValentinaORCID, Cavalli AndreaORCID, Shanbhag Akanksha A., Matkovic Milos, Biggiogero Maira, Maida Pier Andrea, Moritz Jacques, Toscano Chiara, Ghovehoud ElahehORCID, Furlan Raffaello, Barbic FrancaORCID, Voza Antonio, De Nadai Guendalina, Cervia CarloORCID, Zurbuchen YvesORCID, Taeschler PatrickORCID, Murray Lilly A.ORCID, Danelon-Sargenti Gabriela, Moro Simone, Gong Tao, Piffaretti Pietro, Bianchini Filippo, Crivelli Virginia, Podešvová Lucie, Pedotti Mattia, Jarrossay David, Sgrignani Jacopo, Thelen Sylvia, Uhr Mario, Bernasconi EnosORCID, Rauch AndriORCID, Manzo Antonio, Ciurea AdrianORCID, Rocchi Marco B. L., Varani LucaORCID, Moser Bernhard, Bottazzi BarbaraORCID, Thelen MarcusORCID, Fallon Brian A., Boyman OnurORCID, Mantovani AlbertoORCID, Garzoni Christian, Franzetti-Pellanda Alessandra, Uguccioni MariagraziaORCID, Robbiani Davide F.ORCID
Abstract
AbstractInfection with severe acute respiratory syndrome coronavirus 2 associates with diverse symptoms, which can persist for months. While antiviral antibodies are protective, those targeting interferons and other immune factors are associated with adverse coronavirus disease 2019 (COVID-19) outcomes. Here we discovered that antibodies against specific chemokines were omnipresent post-COVID-19, were associated with favorable disease outcome and negatively correlated with the development of long COVID at 1 yr post-infection. Chemokine antibodies were also present in HIV-1 infection and autoimmune disorders, but they targeted different chemokines compared with COVID-19. Monoclonal antibodies derived from COVID-19 convalescents that bound to the chemokine N-loop impaired cell migration. Given the role of chemokines in orchestrating immune cell trafficking, naturally arising chemokine antibodies may modulate the inflammatory response and thus bear therapeutic potential.
Publisher
Springer Science and Business Media LLC
Subject
Immunology,Immunology and Allergy
Reference60 articles.
1. Mehandru, S. & Merad, M. Pathological sequelae of long-haul COVID. Nat. Immunol. 23, 194–202 (2022). 2. Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497–506 (2020). 3. Blomberg, B. et al. Long COVID in a prospective cohort of home-isolated patients. Nat. Med. 27, 1607–1613 (2021). 4. Nalbandian, A. et al. Post-acute COVID-19 syndrome. Nat. Med. 27, 601–615 (2021). 5. Merad, M., Blish, C. A., Sallusto, F. & Iwasaki, A. The immunology and immunopathology of COVID-19. Science 375, 1122–1127 (2022).
Cited by
53 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|